Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ibiayi Dagogo-Jack"'
Autor:
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo-Jack, Nathaniel J. Myall, Georg Richtig, Jillian W. P Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R. Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A. Sosman, Scott Kopetz, Vivek Subbiah, Michael A. Davies, Anna Groover, Ryan J. Sullivan, Keith T. Flaherty, Douglas B. Johnson, Andrea Benedetti, David W. Cescon, Anna Spreafico, George Zogopoulos, April A. N. Rose
PurposeNon-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers in a wide array of cancer types and can be classified into three Classes according to molecular ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db9974e1edba3dd315567ab7951bcfce
https://doi.org/10.1101/2022.02.17.22271120
https://doi.org/10.1101/2022.02.17.22271120
Autor:
Aaron N. Hata, Jennifer L Peterson, Scott L. Weinrich, Satoshi Yoda, Jessica J. Lin, Adam Acker, Aya Shiba-Ishii, Ibiayi Dagogo-Jack, Lesli A. Kiedrowski, Justin F. Gainor, Kristin Dionne, Michele McTigue, Andrew Do, Makeba A Walcott, Mari Mino-Kenudson, Jaimie L. Barth, Ted William Johnson, Beow Y. Yeap, Ping Wei, Linh Nguyen-Phuong, Theodore R. Johnson
The treatment approach to advanced, ALK-positive non-small cell lung cancer (NSCLC) utilizing sequential ALK tyrosine kinase inhibitors (TKIs) represents a paradigm of precision oncology. Lorlatinib is currently the most advanced, potent and selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a276b417464b334652691d18f8ae4c0
https://doi.org/10.1101/2021.07.16.452681
https://doi.org/10.1101/2021.07.16.452681